Regorafenib: hint of minor added benefit
Regorafenib: hint of minor added benefit Advantage in overall survival, but disadvantage in severe side effects Regorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal ...
Read the release